Table 2.
Clinical characteristics of hepatitis B virus-related acute-on-chronic liver failure and hepatitis B virus-related decompensated cirrhosis patients after enrollment
| Characteristics |
HBV-DC |
HBV-ACLF |
P valuea | P valueb | ||
| DC-non-AKI (n = 104) | DC-AKI (n = 28) | ACLF-non-AKI (n = 209) | ACLF-AKI (n = 71) | |||
| Hospitalization (d)1 | 13 (8-20) | 12.5 (9-18.3) | 26 (17-43) | 16 (10.5-33) | 0.144 | < 0.001 |
| Complications | ||||||
| Ascites (%)2 | 80 (76.9) | 28 (100) | 141 (67.5) | 67 (94.4) | 0.570 | < 0.001 |
| HE (%)2 | 8 (7.7) | 3 (10.7) | 41 (19.6) | 31 (43.7) | < 0.001 | < 0.001 |
| GI bleeding (%)2 | 11 (10.6) | 5 (17.9) | 5 (2.4) | 6 (8.5) | 0.151 | 0.002 |
| SBP (%)2 | 22 (21.2) | 19 (67.9) | 68 (32.5) | 47 (66.2) | 0.872 | < 0.001 |
| Pulmonary infection (%)2 | 20 (19.2) | 8 (28.6) | 43 (20.6) | 23 (32.4) | 0.944 | 0.134 |
| Serum creatinine (mg/dL)1 | ||||||
| Baseline | 0.78 (0.68-0.87) | 0.97 (0.81-1.23) | 0.68 (0.6-0.81) | 0.94 (0.74-1.26) | 0.665 | < 0.001 |
| Peak | 0.84 (0.74-0.96) | 1.69 (1.44-2.07) | 0.83 (0.7-0.94) | 1.99 (1.63-2.57) | 0.028 | < 0.001 |
| Final | 0.76 (0.66-0.87) | 1.05 (0.77-1.48) | 0.74 (0.64-0.85) | 1.48 (0.98-2.32) | 0.014 | < 0.001 |
| Treated with terlipressin (%)2 | - | 19 (67.9) | - | 43 (60.6) | 0.499 | - |
| Treatment time1 | - | 5 (3-9) | - | 6 (3-9) | 0.023 | - |
| 30-d mortality2 | 7 (6.7) | 9 (32.1) | 38 (18.2) | 42 (59.2) | 0.015 | < 0.001 |
| 90-d mortality2 | 10 (9.6) | 14 (50) | 69 (33) | 51 (71.8) | 0.039 | < 0.001 |
1
Median (IQR), compared by Mann-Whitney U test or Kruskal–Wallis test;
2
Number (percentage), compared by fisher's exact test or chi-square test;
a
DC-AKI group vs ACLF-AKI group;
b
Compared among all groups. SD: Standard deviation; IQR: Inter-quartile range; HE: Hepatic encephalopathy; GI: Gastrointestinal; SBP: Spontaneous bacterial peritonitis.